CERA conversion to darbepoetin alfa in 154 hemodialysis patients
- PDF / 481,524 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 79 Downloads / 170 Views
NEPHROLOGY - ORIGINAL PAPER
CERA conversion to darbepoetin alfa in 154 hemodialysis patients Yves Dimitrov1,2 · Julie Rieger3 · Thierry Krummel4 · Philippe Petitjean2,5 · Alexandre Klein2,6 · François Chantrel2,7 · Nicolas Meyer8 · Thierry Hannedouche2,4 Received: 23 March 2020 / Accepted: 7 July 2020 © Springer Nature B.V. 2020
Abstract Purpose Anemia is a common complication in dialysis patients, usually treated with erythropoietin (EPO). Among available EPOs and analogs, continuous erythropoietin receptor activator (CERA) and darbepoetin alfa (DA) are the only two agents with a long duration of action, although they have almost never been formally compared in terms of efficacy. We took advantage of an accidental disruption in CERA supply to study the effect of its replacement with DA in the same patients. Methods The clinical and biological characteristics of 154 hemodialysis patients were retrospectively reviewed during the last 3 months on CERA compared to the first 4 months after replacement by DA, both ASE being administered by IV route. The comparison included EPO doses, hemoglobin levels, factors interfering with anemia (iron status assessment, iron doses, inflammation, quality of treatment) and was performed under the Bayesian paradigm. Results We found no significant differences between the two EPOs in terms of doses or hemoglobin concentrations. Factors that could potentially influence hemoglobin concentrations also did not differ under CERA or DA. The stability of hemoglobin was identical with both EPOs. We provide a conversion factor which allows comparison of cost according to local prices. Conclusions We conclude that, in this observational “real life” study, the two EPOs are to be considered as equivalent. Keywords Anemia · Dialysis · ESA · Darbopoetin alpha · CERA Abbreviations ESA Erythropoiesis stimulating agent CERA Continuous erythropoietin receptor activator * Yves Dimitrov yves.dimitrov@ch‑haguenau.fr 1
Nephrology Department, Centre Hospitalier de Haguenau, 64 Avenue du Professeur Leriche, 67500 Haguenau, France
2
Dialysis Unit, AURAL, 5 Rue Henri Bergson, 67200 Strasbourg, France
3
Pharmacy Department, Centre Hospitalier de Haguenau, 64 Avenue du Professeur Leriche, 67500 Haguenau, France
4
Nephrology Department, Hôpitaux Universitaires de Strasbourg, 1 Place de L’Hôpital, 67091 Strasbourg, France
5
Nephrology Department, Clinique St Anne, Rue Philippe Thyss, 67000 Strasbourg, France
6
Nephrology Department, Hôpitaux Civils de Colmar, 39 Avenue de la Liberté, 68024 Colmar, France
7
Nephrology Department, Centre Hospitalier de Mulhouse, 87 Avenue d’Altkirch, 68051 Mulhouse, France
8
Public Health Departement, GRMC, Hôpitaux Universitaires de Strasbourg, 1 Place de L’Hôpital, 67091 Strasbourg, France
DA Darbepoetin alfa EPO Erythropoietin CKD Chronic kidney disease Hb Hemoglobin concentration TSC Transferrin saturation coefficient iPTH Immunoreactive parathyroid hormone CRP C-reactive protein
Introduction Anemia is a common complication in patients
Data Loading...
